How to Get Retatrutide: Your Options in 2026
Retatrutide is not yet FDA approved. Here's a clear breakdown of your legitimate options, what's coming, and what to watch out for.
Investigational (not yet FDA approved). Not legally available for human use outside of clinical trials in the US.
Option 1: Join a Clinical Trial
The only way to access Retatrutide through an official, regulated channel right now is to enroll in an active clinical trial. Eli Lilly is running Phase 3 TRIUMPH trials for Retatrutide across multiple sites in the US and internationally.
- •BMI ≥ 30, or ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, etc.)
- •No current or recent use of GLP-1 receptor agonists (semaglutide, tirzepatide, etc.)
- •No personal or family history of medullary thyroid carcinoma or MEN2
- •No active pancreatitis or severe GI conditions
- •Willing to attend regular in-person study visits
Option 2: Research Peptide Suppliers
A number of US-based peptide research suppliers offer Retatrutide as a research chemical. Quality varies significantly. If you are a researcher evaluating these sources, key quality indicators include:
Option 3: Compounding Pharmacies (Not Currently Available)
Unlike semaglutide and tirzepatide — which became available through compounding pharmacies during drug shortages — Retatrutide cannot legally be compounded. Compounding pharmacies can only compound drugs with an FDA-approved reference product, and Retatrutide has none yet.
What to Expect When Retatrutide Is Approved
Based on Eli Lilly's projected FDA filing in 2026–2027, here's what access will likely look like post-approval:
Alternatives Available Now
If you can't wait for Retatrutide approval, the currently available options with strong clinical backing are:
| Drug | Type | Avg Weight Loss | Status |
|---|---|---|---|
| Tirzepatide (Zepbound) | GIP/GLP-1 dual agonist | ~20–22% | FDA Approved |
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% | FDA Approved |
| Retatrutide | GIP/GLP-1/Glucagon triple | ~24% | Phase 3 Trials |
Frequently Asked Questions
How can I get Retatrutide right now?
Retatrutide is not yet FDA approved. The primary ways to access it are through clinical trials, or as a research chemical from verified peptide suppliers (not for human use).
Is Retatrutide available without a prescription?
Retatrutide is investigational and not available via prescription anywhere. Research-grade versions exist but are sold strictly for laboratory or research use — not for human consumption.
Can I join a Retatrutide clinical trial?
Yes. Eli Lilly is running Phase 3 TRIUMPH trials for Retatrutide. You can search active trials at ClinicalTrials.gov using the identifier NCT05703841 or by searching "retatrutide." Trials typically require BMI ≥ 30 (or ≥ 27 with a weight-related condition) and no recent GLP-1 use.
When will Retatrutide be available to the general public?
Based on current Phase 3 timelines and Eli Lilly's projected FDA filing in 2026–2027, Retatrutide could be available via prescription by 2027–2028 if approved on schedule.
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.